Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | LCAT | P04180 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453576 | 0.86 | HRH3 (0.51) | DPP4HRH3PANK3MALT1CHRM4 | |
| SCHEMBL3452836 | 0.83 | DPP4 (0.53) | DPP4HRH3PANK3CHRM4 | |
| SCHEMBL4183541 | 0.80 | HRH3 (0.54) | DPP4HRH3PANK3MALT1HCRTR1 | |
| SCHEMBL16026705 | 0.78 | PANK3 (0.60) | DPP4HRH3PANK3MALT1CHRM4 | |
| SCHEMBL1990732 | 0.76 | MALT1 (0.59) | DPP4HRH3PANK3MALT1CHRM4 | |
| SCHEMBL3453472 | 0.76 | MAPT (0.44) | DPP4 | |
| SCHEMBL3453678 | 0.76 | KDM4E (0.57) | DPP4PANK3MALT1 | |
| SCHEMBL3082416 | 0.74 | CNR2 (0.59) | DPP4HRH3PANK3MALT1CHRM4 | |
| SCHEMBL5220987 | 0.73 | USP30 (0.57) | DPP4HRH3PANK3MALT1CHRM4 | |
| SCHEMBL13622626 | 0.73 | CHRM4 (0.56) | DPP4HRH3PANK3MALT1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820817-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100105693-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105693-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | DPP4 1539/4885HRH3 138/4885PANK3 2619/4885 |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | ACHE, CHRM5, CHRM3 | DPP4 877/4885HRH3 240/4885PANK3 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.